Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Relapsed, Refractory Multiple Myeloma”

Showing 20 of 0 results

Early research (Phase 1)UnknownNCT04295018
What this trial is testing

BCMA-directed CAR-T Cells Treatment in Subjects With r/r Multiple Myeloma

Who this might be right for
Multiple Myeloma
Peking Union Medical College Hospital 10
Testing effectiveness (Phase 2)Study completedNCT03548207
What this trial is testing

JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-Cell Maturation Antigen (BCMA) in Participants With Relapsed or Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Janssen Research & Development, LLC 126
Testing effectiveness (Phase 2)Ended earlyNCT01646762
What this trial is testing

Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Relapsed or Refractory Multiple Myeloma

Who this might be right for
Refractory Plasma Cell Myeloma
Mayo Clinic 13
Large-scale testing (Phase 3)Active Not RecruitingNCT04181827
What this trial is testing

A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants With Relapsed and Lenalidomide-Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Janssen Research & Development, LLC 419
Testing effectiveness (Phase 2)Study completedNCT01001442
What this trial is testing

Safety and Dose Determining Multi-dose Study of BT062 in Patients With Relapsed or Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Biotest Pharmaceuticals Corporation 35
Testing effectiveness (Phase 2)Looking for participantsNCT06503107
What this trial is testing

Nanobody-based Biepitope CAR-T Cells Targeting BCMA in the Treatment of R/RMM

Who this might be right for
Multiple Myeloma
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology 60
Early research (Phase 1)Looking for participantsNCT06375044
What this trial is testing

Study of SIM0500 Alone in Participants With Relapsed or Refractory Multiple Myeloma

Who this might be right for
Relapsed or Refractory Multiple Myeloma
Jiangsu Simcere Pharmaceutical Co., Ltd. 130
Early research (Phase 1)Ended earlyNCT04855136
What this trial is testing

Safety and Efficacy of bb2121 (Ide-cel) Combinations in Multiple Myeloma

Who this might be right for
Multiple Myeloma
Celgene 21
Testing effectiveness (Phase 2)Study completedNCT03697629
What this trial is testing

An Accelerated Infusion Rate of Daratumumab in Patients With Relapsed and Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma in Relapse
Canadian Myeloma Research Group 40
Early research (Phase 1)Ended earlyNCT05289492
What this trial is testing

Study of Novel Regimens in Relapsed or Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
iTeos Therapeutics 16
Testing effectiveness (Phase 2)Active Not RecruitingNCT04124497
What this trial is testing

A Trial for Relapsed and Relapsed/Refractory Multiple Myeloma Patients

Who this might be right for
Multiple MyelomaDeletion 17P Syndrome
Fondazione EMN Italy Onlus 45
Not applicableUnknownNCT06205823
What this trial is testing

Compare Clinical Outcomes Between Advanced Immunotherapy and Classical Immunochemotherapy in RRMM

Who this might be right for
Myeloma Multiple
Seoul St. Mary's Hospital 1,600
Early research (Phase 1)Study completedNCT00005946
What this trial is testing

Chemotherapy Plus Donor White Blood Cell Infusion in Treating Patients With Relapsed Hematologic Cancer Following Donor Peripheral Stem Cell Transplantation

Who this might be right for
LeukemiaLymphomaMultiple Myeloma and Plasma Cell Neoplasm+1 more
University of Maryland, Baltimore
Very early researchLooking for participantsNCT04657861
What this trial is testing

APRIL CAR-T Cell Therapy for Patients With BCMA/TACI Positive Relapsed and/or Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma in RelapseMultiple Myeloma, Refractory
Zhejiang University 36
Not applicableNot Yet RecruitingNCT06472479
What this trial is testing

LCAR-M61S and LCAR-M61D in Treatment of Relapsed/Refractory Multiple Myeloma

Who this might be right for
Relapsed/Refractory Multiple Myeloma
The First Affiliated Hospital with Nanjing Medical University 66
Testing effectiveness (Phase 2)Study completedNCT03439280
What this trial is testing

Investigate the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of TAK-079 Administered Subcutaneously as a Single Agent in Participants With Relapsed/Refractory (r/r) Multiple Myeloma (MM)

Who this might be right for
Relapsed/RefractoryMultiple Myeloma
Millennium Pharmaceuticals, Inc. 50
Early research (Phase 1)Study completedNCT04322292
What this trial is testing

BCMA-directed CAR-T Cells Treatment in Subjects With r/r Multiple Myeloma

Who this might be right for
Multiple Myeloma
Institute of Hematology & Blood Diseases Hospital, China 9
Early research (Phase 1)Ended earlyNCT03582033
What this trial is testing

A Safety Study of SEA-BCMA in Patients With Multiple Myeloma

Who this might be right for
Multiple Myeloma
Seagen Inc. 83
Early research (Phase 1)Study completedNCT02519452
What this trial is testing

Daratumumab With the Addition of Recombinant Human Hyaluronidase (rHuPH20) for the Treatment of Participants With Relapsed or Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Janssen Research & Development, LLC 120
Testing effectiveness (Phase 2)Study completedNCT02963493
What this trial is testing

Melphalan Flufenamide (Melflufen) Plus Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Oncopeptides AB 157
Next Page

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation